Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 02:01pm CEST

Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND CO
04/20 ELI LILLY AND : Findings in Type 2 Diabetes Reported from Eli Lilly and Company ..
04/20 ELI LILLY AND : Researchers from Eli Lilly and Company Report New Studies and Fi..
04/20 ELI LILLY AND : An Application for the Trademark "ZINLISTIQ" Has Been Filed by E..
04/20 ELI LILLY AND : Reports Summarize Organic Research Study Results from Eli Lilly ..
04/20 ELI LILLY AND : Recent Reports from Eli Lilly and Company Highlight Findings in ..
04/20 ELI LILLY AND : New Findings from Eli Lilly and Company Describe Advances in Eic..
04/20 ELI LILLY AND : Researchers at Eli Lilly and Company Release New Data on Hyperph..
04/20 ELI LILLY AND : New Findings from Eli Lilly and Company in the Area of Osteoporo..
04/20 ELI LILLY AND : Lilly to Present Data for Galcanezumab for the Prevention of Mig..
04/20 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eli Lilly and C..
More news
Sector news : Pharmaceuticals - NEC
03:01a Becton Dickinson to acquire Bard for $24 billion
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/20 Corporate Turnarounds Take Time - Cramer's Mad Money (4/19/17)
04/19 BIOLINERX : COMBAT Engagement
04/18 For $300M, Biogen Beefs Up Its Alzheimer's Attack
04/18 INCYTE : Buy On The Drop?
04/18 Is This Sudden Flight To Safety Temporary?
Advertisement
Financials ($)
Sales 2017 22 108 M
EBIT 2017 5 514 M
Net income 2017 3 688 M
Debt 2017 5 022 M
Yield 2017 2,55%
P/E ratio 2017 28,62
P/E ratio 2018 20,58
EV / Sales 2017 4,31x
EV / Sales 2018 4,21x
Capitalization 90 354 M
More Financials
Chart ELI LILLY AND CO
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 88,8 $
Spread / Average Target 8,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Ricks President, Chief Executive Officer & Director
John C. Lechleiter Chairman
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO11.34%90 354
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.57%200 330
NOVARTIS AG-1.08%192 857
MERCK & CO., INC.5.13%169 673
More Results